HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

AbstractBACKGROUND:
Sequencing of both healthy and disease singletons yields many novel and low frequency variants of uncertain significance (VUS). Complete gene and genome sequencing by next generation sequencing (NGS) significantly increases the number of VUS detected. While prior studies have emphasized protein coding variants, non-coding sequence variants have also been proven to significantly contribute to high penetrance disorders, such as hereditary breast and ovarian cancer (HBOC). We present a strategy for analyzing different functional classes of non-coding variants based on information theory (IT) and prioritizing patients with large intragenic deletions.
METHODS:
We captured and enriched for coding and non-coding variants in genes known to harbor mutations that increase HBOC risk. Custom oligonucleotide baits spanning the complete coding, non-coding, and intergenic regions 10 kb up- and downstream of ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, and TP53 were synthesized for solution hybridization enrichment. Unique and divergent repetitive sequences were sequenced in 102 high-risk, anonymized patients without identified mutations in BRCA1/2. Aside from protein coding and copy number changes, IT-based sequence analysis was used to identify and prioritize pathogenic non-coding variants that occurred within sequence elements predicted to be recognized by proteins or protein complexes involved in mRNA splicing, transcription, and untranslated region (UTR) binding and structure. This approach was supplemented by in silico and laboratory analysis of UTR structure.
RESULTS:
15,311 unique variants were identified, of which 245 occurred in coding regions. With the unified IT-framework, 132 variants were identified and 87 functionally significant VUS were further prioritized. An intragenic 32.1 kb interval in BRCA2 that was likely hemizygous was detected in one patient. We also identified 4 stop-gain variants and 3 reading-frame altering exonic insertions/deletions (indels).
CONCLUSIONS:
We have presented a strategy for complete gene sequence analysis followed by a unified framework for interpreting non-coding variants that may affect gene expression. This approach distills large numbers of variants detected by NGS to a limited set of variants prioritized as potential deleterious changes.
AuthorsEliseos J Mucaki, Natasha G Caminsky, Ami M Perri, Ruipeng Lu, Alain Laederach, Matthew Halvorsen, Joan H M Knoll, Peter K Rogan
JournalBMC medical genomics (BMC Med Genomics) Vol. 9 Pg. 19 (Apr 11 2016) ISSN: 1755-8794 [Electronic] England
PMID27067391 (Publication Type: Journal Article)
Chemical References
  • DNA, Intergenic
  • Protein Isoforms
  • RNA Splice Sites
  • Untranslated Regions
Topics
  • Base Sequence
  • Breast Neoplasms (genetics)
  • DNA, Intergenic (genetics)
  • Exons (genetics)
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Information Theory
  • Inheritance Patterns (genetics)
  • Molecular Sequence Data
  • Mutation (genetics)
  • Nucleic Acid Conformation
  • Ovarian Neoplasms (genetics)
  • Polymorphism, Single Nucleotide (genetics)
  • Protein Binding (genetics)
  • Protein Isoforms (genetics)
  • RNA Splice Sites (genetics)
  • Sequence Alignment
  • Sequence Analysis, DNA
  • Sequence Deletion (genetics)
  • Untranslated Regions (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: